Report of a Phase III study of a Russian drug for the treatment of patients with COVID-19
15 November 2020
The report of the phase III study of the Russian drug for the treatment of patients with COVID-19 was prepared and finalized in a short time.
This drug is intended for the treatment of a wide range of viral infections and is a purine nucleoside that acts as a competitive inhibitor of viral RNA-dependent RNA polymerase.